Evox Therapeutics develops exosome therapeutics for the treatment of serious, life-threatening rare diseases. The company employs a platform-driven technology for this purpose.

Evox Therapeutics

MedPharma is a pharmaceutical company based in the United Kingdom that provides medication and healthcare products.

MedPharma

Evox Therapeutics Ltd | 11,200 followers on LinkedIn. Naturally inspired. Engineered to deliver | Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics.

By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health.

Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs.

Co-founder/Managing Partner, Borealis Ventures

Phil Ferneau

Chief Executive Officer & Co-Founder at Evox Therapeutics Ltd | Non-Executive Director at Combigene (COMBI) & Breakthrough T1D

Per Lundin

Associate Director at Evox Therapeutics

Rajeev Tawar

Principal Scientist at Evox Therapeutics Ltd

David Allcock

Evox Therapeutics Ltd

We proudly congratulate the Samir EL Andaloussi group and all co-authors on publishing their groundbreaking work on the EV engineering platform for the targeted loading and delivery of mRNA, which was featured in Advanced Science! This milestone represents years of collaborative effort, and we are honoured to have partnered with such a talented and dedicated group of researchers. Thank you to all the co-authors and our team at Evox for their commitment and hard work in bringing this cutting-edge innovation to life.

Exciting research stemming from the longstanding collaboration between the team at Evox Therapeutics Ltd and our collaborators at the Karolinska Institutet demonstrates how our exosome-based targeting technology can drive superior extrahepatic delivery and efficacy in a tumor targeting context!

Evox Therapeutics has exciting news to share! Per Lundin has been appointed as the new CEO and Board member. Per has over 15 years of experience in biotech and has previously served as Evox's Co-Founder and Chief Business Officer. With his vast experience, Per is perfectly positioned to lead the company's next growth phase. We would like to extend a huge thank you to Tony for his six years as the CEO. Tony will continue to guide us as a strategic adviser. Under Per's leadership, Evox Therapeutics will continue to focus on advancing our groundbreaking exosome-enabled genetic medicines through our DeliverEX platform. Please join us in welcoming Per to his new role and wishing Tony the best in his future endeavours! #Leadership #Biotechnology #ExosomeTherapeutics #Innovation #EvoxTherapeutics

We are proud to announce that Antonin de Fougerolles will present Evox Therapeutics' latest advancements at the Tokyo Symposium & Workshop on Genomic Medicine, Therapeutics, and Health. Tony will delve into our progress in exosome-based therapies. Join us to hear about the transformative potential of our research and the future implications for health and disease treatment!

We are excited to share that our CEO, Antonin de Fougerolles , will speak at the "Delivery of Nucleic Acid Therapeutics" conference in Siracusa, Sicily. This conference brings together genetic medicine experts to discuss cutting-edge solutions for delivering nucleic acid therapeutics. We invite you to follow this event with us. Find all the details at https://lnkd.in/eDXnvAAs

Happy International Women’s Day! A great list from #NobelPrize , honouring the extraordinary women and their groundbreaking achievements which have left an indelible mark on the world. #iwd2024

As Rare Disease Day is marked, we continue our effort to progress exosome-based genetic medicines. Our path is fueled by a deep commitment to those facing rare diseases, with every step forward bringing us closer to new treatments. Today, we want to acknowledge the collective endurance and hope of those living with rare diseases, emphasizing our ongoing research efforts and the journey ahead. Learn more and support the movement at https://lnkd.in/gk6hbAF #RareDiseaseDay #EvoxTherapeutics

Discover the latest advancements in genetic medicine and the transformative impact of exosome delivery systems on treating rare diseases with PharmaTimes' new article. A must-read for those interested in healthcare innovation! #GeneticMedicine #Exosomes #Innovation #PharmaTimes #Evox

We're excited to be featured by Labiotech.eu as one of the leading UK biotech companies! Our focus on developing exosome-based therapeutics aims to address challenging diseases. Being part of the UK's dynamic biotech scene is a privilege, and we're eager to contribute to transforming healthcare. Check out the article to learn more about us and other innovators in the field. #Biotech #Innovation #EvoxTherapeutics #exosomes

Metric
Company Name	Evox Therapeutics	MedPharma
Symbol
MSH ID	COM:EVOXTHERAPEUTICS	UK:MEDPHARMA
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	GB	GB
Stage		Venture Round
Employee Count
Website	evoxtherapeutics.com	medpharma.uk
LinkedIn	evox-therapeutics-ltd	medpharm
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		1.50K
Web Traffic Growth		-0.24
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

EVOX

COM:EVOXTHERAPEUTICS

Evox Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue